About this episode

This episode discusses recent FDA regulatory decisions related to dermatology, including treatments for psoriasis and lupus, and addresses Eosinophilic Fasciitis and concerns about fibromyalgia.

This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia?Show Notes:1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP 3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7 4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS 5.vUCB announced topline…

People in this episode

Host: Dr. Cush

Topics covered

• FDA approvals
• dermatology
• psoriasis
• lupus
• Eosinophilic Fasciitis
• fibromyalgia

Keywords

• FDA
• Icotrokinra
• psoriasis
• lupus
• Eosinophilic Fasciitis
• deucravacitinib
• bimekizumab
• risankizumab
• clinical trials

Mentioned in this episode

Organizations: FDA

Products: Icotrokinra, secukinumab, tildrakizumab, deucravacitinib, bimekizumab, risankizumab

Places: United States

More episodes of Rheumnow Podcast

• Follow the Money (4.23.2026) · April 24, 2026 · 26 min
• Prescribing Lessons (4.17.2026) · April 17, 2026 · 25 min
• Top Four and More (4.10.2026) · April 10, 2026 · 26 min
• Whats New PsA? (4.3.2026) · April 3, 2026 · 21 min
• PsA GRAPPA Domains: Outcomes With a JAKi · April 1, 2026 · 18 min
• Moral Distress (3.27.2026) · March 27, 2026 · 27 min

Explore listener stats, chart rankings, contacts and more on the Rheumnow Podcast podcast page.